Adenovirus-mediated wild-typep53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer

AbstractBackground: Thep53 tumor suppressor gene is mutated in up to 70% of pancreatic adenocarcinomas. We determined the effect of reintroduction of the wild-typep53 gene on proliferation and apoptosis in human pancreatic cancer cells using an adenoviral vector containing the wild-typep53 tumor suppressor gene. Methods: Transduction efficiencies of six p53-mutant pancreatic cancer cell lines (AsPC-1, BxPC-3, Capan-1, CFPAC-1, MIA PaCa-2, and PANC-1) were determined using the reporter gene construct Ad5/CMV/β-gal. Cell proliferation was monitored using a3H-thymidine incorporation assay, Western blot analysis forp53 expression was performed, and DNA laddering and fluorescence-activated cell sorter analysis were used to assess apoptosis.p53 gene therapy was tested in vivo in a subcutaneous tumor model. Results: The cell lines varied in transduction efficiency. The MIA PaCa-2 cells had the highest transduction efficiency, with 65% of pancreatic tumor cells staining positive for beta-galactosidase (β-gal) at a multiplicity of infection (MOI) of 50. At the same MOI, only 15% of the CFPAC-1 cells expressed the β-gal gene. Adenovirus-mediatedp53 gene transfer suppressed growth of all human pancreatic cancer cell lines in a dose-dependent manner. Western blot analysis confirmed the presence of the p53 protein product at 48 hours after infection. DNA ladders demonstrated increased chromatin degradation, and fluorescence-activated cell sorter analysis demonstrated a four-fold increase in apoptotic cells at 48 and 72 hours following infection with Ad5/CMV/p53 in the MIA PaCa-2 and PANC-1 cells. Suppression of tumor growth mediated by induction of apoptosis was observed in vivo in an established nude mouse subcutaneous tumor model following intratumoral injections of Ad5/CMV/p53. Conclusions: Introduction of the wild-typep53 gene using an adenoviral vector in pancreatic cancer withp53 mutations induces apoptosis and inhibits cell growth. These data provide preliminary support for adenoviral mediatedp53 tumor suppressor gene therapy of human pancreatic cancer.

[1]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[2]  R. Hruban,et al.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.

[3]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[4]  T. Tamiya,et al.  Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. , 1994, Human gene therapy.

[5]  H. Saeger,et al.  Survival After Pancreatoduodenectomy: 118 Consecutive Resections Without an Operative Mortality , 1990, Annals of surgery.

[6]  J. Roth,et al.  Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.

[7]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[8]  J. Roth,et al.  p53 Suppressor Gene , 1995, Molecular Biology Intelligence Unit.

[9]  K. Conlon,et al.  The molecular genetics of pancreatic cancer. , 1997, Surgical oncology.

[10]  W. Anderson,et al.  Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. , 1996, Annals of surgery.

[11]  T. Sekiya,et al.  Association of p53 Gene Mutations with Short Survival in Pancreatic Adenocarcinoma , 1995, Japanese journal of cancer research : Gann.

[12]  J. Roth,et al.  High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. , 1994, Cancer gene therapy.

[13]  Jeffrey E. Lee,et al.  Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head* , 1996 .

[14]  H. Friess,et al.  p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. , 1993, Cancer letters.

[15]  F. Graham,et al.  Manipulation of adenovirus vectors. , 1991, Methods in molecular biology.

[16]  J. Roth,et al.  In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. , 1996, Anticancer research.

[17]  S. Ellenberg,et al.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. , 1985, Archives of surgery.

[18]  F. Real,et al.  Comparative analysis of mutations in the p53 and K‐ras genes in pancreatic cancer , 1994, International journal of cancer.

[19]  J. Roth,et al.  Safety evaluation of Ad5CMV-p53 in vitro and in vivo. , 1995, Human gene therapy.

[20]  B. Vogelstein.  A deadly inheritance , 1990, Nature.

[21]  P. Hall,et al.  Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer , 1992, British Journal of Cancer.

[22]  B. Vogelstein.  Cancer. A deadly inheritance. , 1990, Nature.

[23]  T. McDonnell,et al.  Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. , 1995, Cancer research.

[24]  F. Mícek.  [Cancer of the pancreas]. , 1965, Bratislavske lekarske listy.

[25]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[26]  J. Roth,et al.  Safety Evaluation of Ad5CMY-p53 In Vitro and In Vivo , 1995 .

[27]  S. Orrenius,et al.  Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. , 1989, The Journal of biological chemistry.

[28]  J. Roth,et al.  Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  N. Pellegata,et al.  K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. , 1994, Cancer research.

[30]  Jeffrey E. Lee,et al.  Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[32]  A. Klein-Szanto,et al.  Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. , 1992, Oncogene.